Zepbound, tirzepatide, was approved on Nov 8 by the FDA. Expect it to be available in the coming months. This is yet another injectable weight-loss drug to hit the market and is the same formula as the already approved Wegovy that is indicated for type 2 diabetes.
It activates both GIP, glucose-dependent isulinotropic polypeptide, and GLP-1, glucagon-like peptide-1, hormone receptors.

Criteria for use are a BMI greater than 30 or a BMI between 25-30 with another chronic condition like obstructive sleep apnea, high blood pressure, high cholesterol, and diabetes.

At the highest dose, Zepbound lead to 25% loss of body weight in the SURMOUNT-1 and SURMOUNT-2 trials.

Nausea, vomiting, and abdominal pain are common adverse effects. Although rare, sometimes side effects can be severe and it may lead to severe stomach problems, kidney problems, gallbladder problems, pancreatitis, allergic reactions, low blood sugar, changes in vision or depression and thoughts of suicide.

This and other GLP-1 and GIP activators should not be used if you have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

As always, everyone’s situation is unique, so please discuss the risks and benefits with your provider.

I hope this is helpful!